Plain Language Patient Summary Changes to treatment strategies for people living with type 2 diabetes

Date of summary: December 2020

- This plain language patient summary is intended for a non-clinician audience. It summarizes content from one chapter in the supplement Type 2 Diabetes 2021, a collection of articles written for family physicians and other family health care professionals.
- The medicines discussed in this summary are approved to treat type 2 diabetes.

What did this chapter look at?

- This chapter looks at how approaches to treatment for people with type 2 diabetes and other health conditions have changed over time.
- Type 2 diabetes is a common health condition where the level of sugar (glucose) in the blood is increased. It affects around 34 million people in the United States.
- People with type 2 diabetes are more likely to develop other health conditions, as shown below.

3 in 10 will develop **cardiovascular disease** – a general term for a wide range of health conditions that affect the heart and blood vessels

4 in 10 will develop **chronic kidney disease** – a health condition where the kidneys do not work as well as they should

3 in 10 will develop **heart failure** – a health condition where the heart stops pumping blood around the body as well as it should

8 in 10 will develop high blood pressure (hypertension)

8 in 10 will develop high levels of cholesterol and other fats in the blood (dyslipidemia)

8 in 10 will become overweight or obese

How have treatment strategies changed over time?

- In the past, the main aim of treatment was to maintain a low blood sugar level.
- Health care professionals measure the proportion of a blood protein (hemoglobin) that has sugar attached to it to indicate a person's average blood sugar levels over time. This is known as the glycated hemoglobin (A1c) level.
- More recent evidence suggests that considering other health conditions that people with type 2 diabetes may have can have benefits. These benefits include better control of their type 2 diabetes and improved survival.
- Reducing A1c levels is still a key aim of treatment, but the target level may vary depending on the individual. Personalizing blood sugar treatment targets based on whether a person has other health conditions can ultimately improve their long-term quality of life.

7.0%

A target A1c that is generally appropriate for adults who are not pregnant.

GID

⎄

6.5% A lower target A1c may be preferred when it can be achieved safely.

8.0% A higher target A1c may be considered if a person has other health conditions, a limited life expectancy, or is at risk of having very low blood sugar levels (severe hypoglycemia).

What medicines did the authors look at?

- Lifestyle changes, such as increased exercise and changes to diet, can help to improve blood sugar. Many people need medicine too.
- Metformin is usually the first choice of medicine for people with type 2 diabetes.
 - Metformin works by decreasing the amount of sugar the liver releases into the blood.
 - Metformin also helps the body respond better to insulin. Insulin is a hormone that helps control blood sugar levels.
 - People may need additional medicines over time to reach and maintain treatment targets for type 2 diabetes. These medicines usually are added to metformin but may be used alone.
- The boxes below show how 5 groups of type 2 diabetes medicines work. The boxes also show medicines in that group the generic name is first and the brand or trade name is in parentheses.

Sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors)

Help the kidneys to remove extra sugar from the body.

- Canagliflozin (Invokana®)
- Dapagliflozin (Farxiga[®])
- Empagliflozin (Jardiance[®])
- Ertugliflozin (Steglatro[®])
- Combination pills with other medicines, like metformin, are also available

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)

Increase incretin levels (a gut hormone). This helps the body produce more insulin and lower blood sugar levels when needed.

- Dulaglutide (Trulicity[®])
- Exenatide (Byetta[®])
- Exentide XR (Bydureon[®] and Bydureon BCise[®])
- Liraglutide (Victoza[®])
- Lixisenatide (Adlyxin[®])
- Semaglutide (tablet: Rybelsus[®]; injection: Ozempic[®])

Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors)

Help the body produce more insulin and lower blood sugar levels when needed.

- Alogliptin (Nesina[®])
- Linagliptin (Tradjenta[®])
- Saxagliptin (Onglyza[®])
- Sitagliptin (Januvia[®])
- Combination pills with other medicines, like metformin, are also available

Sulfonylureas

Increase the amount of insulin made by the pancreas.

- Glipizide (Glucotrol[®], Glucotrol XL[®] [extended release], generics available)
- Glyburide (Diabeta[®], Glynase[®], generics available)
- Glimepiride (Amaryl[®], generics available)
- Tolbutamide (no brand name)

Thiazolidinediones

Help the body better use insulin.

- Pioglitazone (Actos[®])
- Rosiglitazone (Avandia[®])
- Combination pills with other medicines, like metformin, are also available

(})) How to say

- Alogliptin (a-low-GLIP-tin). It is also called Nesina (ness-EE-na)
- Canagliflozin (can-A-gli-FLOW-zin). It is also called Invokana (in-VO-CAHN-a)
- **Dapagliflozin** (dap-A-gli-FLOW-zin). It is also called **Farxiga** (far-ZEE-ga)
- **Dulaglutide** (du-la-GLOO-tide). It is also called **Trulicity** (true-LI-city)
- Dyslipidemia (dys-lip-id-emia)
- **Empagliflozin** (em-PAH-gli-FLOW-zin). It is also called **Jardiance** (JAR-dee-ance)
- Ertugliflozin (err-TUG-gli-FLOW-zin). It is also called Steglatro (ste-GLA-trow)
- Exenatide (eck-SEN-a-tide) and exenatide XR. It is also called Byetta (bi-ET-ta) and Bydureon (bi-door-E-ON)

- **Glimepiride** (GLIH-meh-peh-ride). It is also called **Amaryl** (A-mah-rill)
- Glipizide (GLIP-eh-zide). It is also called Glucotrol (GLUE-co-trol) or Glucotrol XL
- Glyburide (GLY-bur-ide). It is also called Diabeta (DIE-a-beta) or Glynase (GLY-neh-es)
- Hemoglobin (HE-mo·GLO·bin)
- **Hypoglycemia** (hi-POH-gly-SEE-mee-ah)
- Linagliptin (lin-ah-GLIP-tin). It is also called Tradjenta (tra-GENT-a)
- Liraglutide (leer-a-GLOO-tide). It is also called Victoza (VIC-toe-za)
- Lixisenatide (LICK-see-SEN-a-tide). It is also called Adlyxin (ADD-eh-licks-en)
- Metformin (met-FORM-in)
- Pioglitazone (PIE-oh-gli-ta-zone). It is also

called Actos (ACK-toes)

- **Rosiglitazone** (RO-si-gli-ta-zone). It is also called **Avandia** (Ah-van-dee-ah).
- **Saxagliptin** (SAX-a-GLIP-tin). It is also called **Onglyza** (on-GLEE-za)
- Semaglutide (sem-a-GLOO-tide). The tablet is also called Rybelsus (rie-BELL-sus), the injection is also called Ozempic (OH-sem-pick)
- **Sitagliptin** (sit-ah-GLIP-tin). It is also called **Januvia** (jan-OO-vee-a)
- Sulfonylurea (SULF-fah-nil-yoo-ree-ah)
 Thiazolidinedione
- (THIGH-ah-ZO-li-deen-DYE-own)
- Tolbutamide (TOLL-bute-ah-mide)

How do other health conditions affect treatment choice?

Other health conditions	Considerations for glucose-lowering treatment
Conditions that affect the heart or blood vessels (cardiovascular disease)	• Certain blood sugar-lowering medicines such as SGLT2 inhibitors and GLP-1 RAs may be preferred, as they can reduce the risk of negative cardiovascular outcomes.
GID Reduced kidney function	 Some medicines including metformin may not be safe for people who have severe kidney problems. SGLT2 inhibitors and GLP-1 RAs may be useful if people need an additional blood sugar-lowering medicine or cannot take metformin. SGLT2 inhibitors may prevent kidney function from getting worse.
Heart failure	 People with unstable heart failure should avoid metformin. In people with established heart failure, SGLT2 inhibitors can help to reduce the risk of hospitalization. People with heart failure should avoid thiazolidinediones, as they are associated with an increased risk of heart failure.
Overweight/ obesity	 Some blood sugar-lowering medicines can affect body weight, and a health care professional may bring this up when discussing which medication to use. Weight loss Weight loss Weight neutral Weight neutral Weight gain Thiazolidinediones, sulfonylureas, insulin

What are the key take-home points?

- Type 2 diabetes affects a wide range of people, and there is no one-size-fits-all approach to treatment.
- People with type 2 diabetes are more likely to develop other health conditions.
- Any treatment strategies for people with type 2 diabetes should be tailored to the individual, taking into account other conditions they may have, any personal preferences, and treatment cost.

Summary prepared by Andy Shepherd of Elevate Scientific Solutions. The author is a paid employee of Envision Pharma Group. Plain language services were funded by Boehringer Ingelheim Pharmaceuticals, Inc. Drs. Shubrook and Pfotenhauer, authors of the original article, reviewed and approved this summary. This supplement was sponsored by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.